SAVA - NASDAQ

Cassava Sciences, Inc.

Cassava Sciences, Inc.

SAVA·NASDAQ

$1.96

-6.5%
HealthcareBiotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$94.44M
EPS-1.8800
P/E Ratio-1.04
Earnings Date03/16/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Cassava Sciences, Inc.

Cassava Sciences, Inc. Earnings Call Transcripts

SAVA · NASDAQ

2024

2
Q2
Aug 8
Q3
Nov 7
Q1
N/A
Q4
N/A

2018

1
Q3
Oct 29
Q1
N/A
Q2
N/A
Q4
N/A

2014

2
Q2
Aug 5
Q3
Oct 30
Q1
N/A
Q4
N/A

Related Guides

Blog Categories

Continue your SAVA research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.